中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
12期
1-3
,共3页
代谢综合征%载脂蛋白B/载脂蛋白A1比值%瑞舒伐他汀%阿托伐他汀
代謝綜閤徵%載脂蛋白B/載脂蛋白A1比值%瑞舒伐他汀%阿託伐他汀
대사종합정%재지단백B/재지단백A1비치%서서벌타정%아탁벌타정
Metablic syndrome%ApoB/ApoA1 ratio%Rosuvastatin%Atorvastatin
目的 观察瑞舒伐他汀对代谢综合征(MS)患者载脂蛋白B/载脂蛋白A1 (ApoB/ApoA1)的影响.方法 将60例MS患者分为两组,瑞舒伐他汀组(30例)给予舒夫坦10mg/d治疗,阿托伐他汀组(30例)给予立普妥20mg/d治疗.随访12周,观察研究前后血脂、血糖、血压、尿白蛋白排泄率(UAER)、体重指数(BMI)、肝功能、肾功能、肌酸激酶、血常规的变化.结果 治疗4周后两组分别较治疗前ApoB/ApoA1、ApoB、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)显著下降(P均＜0.01),ApoA1、高密度脂蛋白胆固醇(HDL-C)有增高趋势,但差异无统计学意义,余指标两组比较差异无统计学意义.治疗12周后两组分别较治疗前及治疗4周后ApoB/ApoA1、ApoB、TC、LDL-C、TG及收缩压、舒张压、UAER显著下降(P均＜0.01),ApoA1、HDL-C有继续增高趋势,但差异无统计学意义,余指标两组比较差异无统计学意义.结论 瑞舒伐他汀可改善MS患者的血脂紊乱,降低ApoB/ApoA1比值.
目的 觀察瑞舒伐他汀對代謝綜閤徵(MS)患者載脂蛋白B/載脂蛋白A1 (ApoB/ApoA1)的影響.方法 將60例MS患者分為兩組,瑞舒伐他汀組(30例)給予舒伕坦10mg/d治療,阿託伐他汀組(30例)給予立普妥20mg/d治療.隨訪12週,觀察研究前後血脂、血糖、血壓、尿白蛋白排洩率(UAER)、體重指數(BMI)、肝功能、腎功能、肌痠激酶、血常規的變化.結果 治療4週後兩組分彆較治療前ApoB/ApoA1、ApoB、總膽固醇(TC)、低密度脂蛋白膽固醇(LDL-C)、甘油三酯(TG)顯著下降(P均＜0.01),ApoA1、高密度脂蛋白膽固醇(HDL-C)有增高趨勢,但差異無統計學意義,餘指標兩組比較差異無統計學意義.治療12週後兩組分彆較治療前及治療4週後ApoB/ApoA1、ApoB、TC、LDL-C、TG及收縮壓、舒張壓、UAER顯著下降(P均＜0.01),ApoA1、HDL-C有繼續增高趨勢,但差異無統計學意義,餘指標兩組比較差異無統計學意義.結論 瑞舒伐他汀可改善MS患者的血脂紊亂,降低ApoB/ApoA1比值.
목적 관찰서서벌타정대대사종합정(MS)환자재지단백B/재지단백A1 (ApoB/ApoA1)적영향.방법 장60례MS환자분위량조,서서벌타정조(30례)급여서부탄10mg/d치료,아탁벌타정조(30례)급여립보타20mg/d치료.수방12주,관찰연구전후혈지、혈당、혈압、뇨백단백배설솔(UAER)、체중지수(BMI)、간공능、신공능、기산격매、혈상규적변화.결과 치료4주후량조분별교치료전ApoB/ApoA1、ApoB、총담고순(TC)、저밀도지단백담고순(LDL-C)、감유삼지(TG)현저하강(P균＜0.01),ApoA1、고밀도지단백담고순(HDL-C)유증고추세,단차이무통계학의의,여지표량조비교차이무통계학의의.치료12주후량조분별교치료전급치료4주후ApoB/ApoA1、ApoB、TC、LDL-C、TG급수축압、서장압、UAER현저하강(P균＜0.01),ApoA1、HDL-C유계속증고추세,단차이무통계학의의,여지표량조비교차이무통계학의의.결론 서서벌타정가개선MS환자적혈지문란,강저ApoB/ApoA1비치.
Objective To observe the effect of rosuvastatin on ApoB/ApoA1 in patients with metablic syndrome(MS).Methods Sixty patients with MS were divided into two groups,30 patients in rosuvastatin group received schufftan 10 mg/d and 30 cases in atorvastatin group received lipitor 20 mg/d.The blood lipids,plasma glucose,blood pressure,urinary albumin excretion rates( UAER),body mass index( BMI),hepatic and renal function,creatine kinase( CK),blood routine were measured before and after 4-weeks,12-weeks treatment.Results After 4-weeks treatment,the plasma levels of ApoB/ApoA1,ApoB,TC,LDL-C,TG decreased obviously in both groups (P ＜ 0.01 ).The plasmalevels of ApoA1 and HDL-C tended to increase,but there were no significant differences,other parameters were not signifcantly different,the above-mentioned indicators between the two groups at the 4thweek follow-up were not significantly different.After 12-weeks treatment,the plasma levels of ApoB/ApoA1,ApoB,TC,LDL-C,TG decreased significantly than before treatment and after 4-week follow-up in the two groups,respectively (P ＜ 0.01 ),but there were no statistically significant differences in ApoA1,HDL-C,the plasma level of ApoB/ApoA1,ApoB,TC,LDL-C in the rosuvastatin group were lower than those in the atorvastatin group at the 12th-week follow-up ( P ＜ 0.05).Conclusions Rosuvastatin can ameliarate dyslipidemia in MS patients and reduce ApoB/ApoA1 ratio.
